Secondary Prophylaxis Gastric Variceal Bleed

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators conducted a randomized, controlled trial (RCT) to study the efficacy of beta blockers versus endoscopic cyanoacrylate injection in the prevention of gastric variceal (GOV2 or IGV1) rebleeding and improvement in survival.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Govind Ballabh Pant Hospital
• Treatments: Adrenergic beta-Antagonists; Propranolol

Criteria

Inclusion Criteria:

• Patients with GOV2 without esophageal varix or IGV1, who had bled from GV were included

Exclusion Criteria:

• Presence of esophageal varix

• GOV2 with GOV1; contraindications to beta-blocker therapy and cyanoacrylate injection

• Prior injection of cyanoacrylate or sclerotherapy for GV or GV ligation, transjugular intrahepatic portosystemic shunt, balloon-occluded retrograde transvenous obliteration, balloon-occluded endoscopic injection sclerotherapy of GV, shunt operation for prevention of rebleeding from GV

• Patients already on beta-blocker or nitrates

• Undetermined origin of bleeding from esophageal varix or gastric varix

• Hepatic encephalopathy grade III/IV

• Hepatorenal syndrome

• Hepatocellular carcinoma

• Presence of deep jaundice (serum bilirubin > 10 mg/dl)

• Uremia

• Cerebrovascular accident

• Cardiorespiratory failure

• Pregnancy or patients not giving informed consent for endoscopic procedures